Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC22A4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC22A4 Partial ECD Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View SLC22A4 Products |
| Gene Delivery | SLC22A4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Crucial for preserving 12-transmembrane conformation. |
View SLC22A4 Products |
| Benchmark Ab | Anti-SLC22A4 Recombinant Antibody Recombinant positive control for surface expression validation. |
View SLC22A4 Products |
| Validator | SLC22A4 siRNA Set For knockdown verification in functional transport assays. |
View SLC22A4 Products |
| Related Target A | SLC22A5 (OCTN2) High-homology transporter. Essential for off-target selectivity screening to prevent systemic carnitine depletion. |
View SLC22A5 Products |
| Related Target B | SLC22A1 (OCT1) Major hepatic organic cation transporter. Key counter-target for ADME/Tox profiling. |
View SLC22A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of 12-TMD Protein | Lentivirus-mediated stable cell line construction ensures native membrane insertion and functional transport activity. |
| Subfamily Off-target Screening (SLC22A5/OCTN2) | Sequence-verified recombinant homolog proteins and overexpression cell lines available for strict cross-reactivity profiling. |
| Lack of Validated Controls | Sequence-defined clinical benchmark antibodies and positive control reagents included. |
| False Positive Transport Inhibition | Validated siRNA sets included for target-specific knockdown verification in substrate uptake assays. |
Live SLC22A4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC22A4 (OCTN1) therapeutics is intensifying, with major players shifting focus from traditional systemic anti-inflammatory agents to gut-restricted small molecule inhibitors and targeted transport modulators. As first-generation therapies for inflammatory bowel disease (IBD) reach the clinic, the next wave of R&D is targeting the specific L503F missense mutation associated with Crohn's disease susceptibility, as well as exploiting SLC22A4 over-expression in colorectal and esophageal cancers to deliver cytotoxic payloads.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Crohn's Disease, Rheumatoid Arthritis | Functional uptake assays (Need Lentivirus for stable cell line generation) |
| Monoclonal Antibodies | Global Biopharma | Autoimmune Disorders, Inflammatory Diseases | Cell-surface binding assays (Need sequence-verified ECD antigens) |
| Substrate-Drug Conjugates | Oncology-focused Biotechs | Colorectal Cancer, Solid Tumors | Intracellular accumulation assays (Need validated siRNA knockdown controls) |